ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Impact of implementation process on long-acting cabotegravir/rilpivirine prescription at 9 HIV clinics, 2021-2024.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Long-Acting Injectable Cabotegravir HIV PrEP Uptake, Adherence, and Persistence in Two Large US Integrated Healthcare Systems.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Implementation of Long-Acting Cabotegravir/Rilpivirine in US HIV Care Settings: Results From a National Survey of Frontline Clinicians.Open forum infectious diseases · 2026Article
- Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Real-World Impact of Insurance Changes on Long-acting Cabotegravir Plus Rilpivirine Delivery.Open forum infectious diseases · 2026Article
- Brief Report: To Err Is Human, to Persist Is Diabolical: Are We Repeating the Same Cost and Insurance Coverage Mistakes Again With Injectable PrEP?Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Scalability Metrics and Effort Requirements for a Long-Acting Injectable Antiretroviral Treatment Program.Open forum infectious diseases · 2026Article
- HIV Preexposure Prophylaxis Utilization and Reasons for Never Using Preexposure Prophylaxis Among Transfeminine Persons in the United States: Findings From the Transgender Women's Internet Survey and Testing (TWIST) Study.Open forum infectious diseases · 2026Article
- "Nobody's Going to Say No to a Dollar": Framing HIV Medication Diversion Through the Lens of Economies of Diversion.AIDS and behavior · 2026Article
- Comparing Interest in Thigh Administration of Long-acting Cabotegravir/Rilpivirine Among Hypothetical Users, Early Adopters, and Trial Participants With Experience.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Discontinuation of Long-acting Injectable Cabotegravir-Rilpivirine in a Large Clinic Cohort.Open forum infectious diseases · 2025Article
- Perceptions of Long-Acting Injectable Pre-Exposure Prophylaxis Among Men Who Have Sex With Men and Transgender Individuals in Europe Using Structural Text Modeling Technique: Cross-Sectional Study.JMIR public health and surveillance · 2025Article
- Oral PrEP use and intention to use long-acting PrEP regimens among MSM accessing PrEP via governmental and non-governmental provision pathways, 20 European countries, October 2023 to April 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Lenacapavir: a potential game changer for HIV prevention in the Americas, if the game is played equitably.Lancet regional health. Americas · 2025Review
- Health Worker Experiences and Perspectives on the Integration of Long-Acting Injectable Antiretroviral Therapy into a Safety-Net HIV Clinic in the Southeastern United States.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Long-acting injectables (LAIs) for HIV prevention and treatment could dramatically improve health outcomes and health equity for people with HIV and those who could benefit from pre-exposure prophylaxis. Despite widespread acceptability and demand by providers and potential users of LAIs, implementation has been extremely limited since the introduction of cabotegravir/rilpivirine, the first LAI for HIV treatment, in January 2021, and long-acting cabotegravir, the first LAI for HIV prevention, in December 2021. We report results of a provider survey, conducted by the HIV Medicine Association, which identified LAI implementation barriers related to health insurance processes, staffing and administrative support, drug costs and acquisition, and access for individuals who are uninsured. We provide policy recommendations to address those barriers and facilitate broad and equitable access to LAIs for HIV prevention and treatment, which will be necessary to achieve the goals of the US Ending the HIV Epidemic initiative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.